Læknaneminn - 01.04.1999, Blaðsíða 53

(radiofrequency ablation) hjá þeim sem fá tíð köst af
sleglahraðtakti.
SAMANTEKT:
Igrædd hjartarafstuðstæki eru gagnleg viðbót við
lyfjameðferð á hraðatakttruflunum með uppruna í
sleglum. Niðurstöður nýlegra rannsókna benda til
þess að þessi meðferð sé áhrifarík og muni líkast til
verða beitt í vaxandi mæli við sleglahraðatakt á næstu
árum.
HEIMILDIR
1. Mirowski M, Reid PR, Mower M, et al. Termination of
malignant ventricular tachyarrhythmias with an implanted
automatic defibrillator in humans. N Engl J Med
1980;303:322-24.
2. Madan N, Saksena S. Indications and patient selection for ICD
therapy. In: Interventional electrophysiology. I Singer (ed.),
Williams and Wilkins, Baltimore Md, 1997, pp 687-702.
3. The Antiarrhytmics versus Implantable Defibrillators In-
vestigators. A comparison of antiarrhythmic drug therapy with
implantable defibrillators in patients resuscitated from near
fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-
83.
5. The Cardiac Arrhythmia Suppression Trial (CAST) In-
vestigators. Prelimiary Report: effect of encainide and fle-
cainide on mortality in a randomized trial of arrhythmia sup-
pression after acute myocardial infarction. N Engl J Med
1989;321:406-12.
6. Waldo AL, Camm AJ, Cooper W, et al. Effect of d-sotalol on
mortality in patients with left ventricular dysfunction after
recent and remote myocardial infarction. Lancet 1996;348:7-
12.
7. Cairns, JA, Connolly SJ, Roberts R, et al. Randomized trial of
outcome after myocardial infarction in patients with frequent
or repetitive premature ventricular contractions. Canadian
Amiodarone Myocardial Infarction Trial (CAMIAT). Lancet
1997;349:675-682.
8. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of
effect of amodarone on mortality in patients with left
ventricular dysfunction after recent myocardial infarction:
European Myocardial Amiodarone Trial (EMIAT). Lancet
1997;349:667-674.
9. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with
an implanted defibrillator in patients with coronary artery
disease at high risk for ventricular arrhythmia. N Engl J Med
1996;335:1933-40.
10. Pinski SL, Trohman RG. Implantable cardioverter defi-
brillators: Implications for the non-electrophysiologist. Ann
Int Med 1995:120:770-777.
4. Cappato R. Secondary prevention of sudden death: The Dutch
study, the Antiarrhythmics versus Implantable Defibrillator
Trial, the Cardiac Arrest Study, Hamburg, and the Canadian
Implantable Defibrillator Study. Am J Cardiol I999;83:680-
730.
LÆKNANEMINN • 1. tbl. 1999, 52. árg.
49